Rhythm Pharmaceuticals (RYTM) Current Deferred Revenue (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 9 years of Current Deferred Revenue data on file, last reported at $48000.0 in Q1 2026.

• On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $48000.0 in Q1 2026; TTM through Mar 2026 was $48000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $194000.0, down 84.91% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $48000.0, down from $194000.0 in the prior quarter.
• Over the last five years, Current Deferred Revenue for RYTM reached as high as $9.4 million in Q1 2022 and fell as low as $48000.0 in Q1 2026.
• Historically, Current Deferred Revenue has averaged $1.8 million across 5 years, with a median of $1.3 million in 2023.
• Across the five-year window, Current Deferred Revenue changed 0.0% in 2024 and plunged 84.91% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $1.4 million in 2022, then fell by 10.32% to $1.3 million in 2023, then changed by 0.0% to $1.3 million in 2024, then plunged by 84.91% to $194000.0 in 2025, then sank by 75.26% to $48000.0 in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $48000.0 in Q1 2026, $194000.0 in Q4 2025, and $1.3 million in Q4 2024.